-+ 0.00%
-+ 0.00%
-+ 0.00%

CARsgen says CT0596 wins NMPA IND clearance for relapsed/refractory multiple myeloma

PUBT·08/04/2026 00:01:44
Listen to the news
CARsgen says CT0596 wins NMPA IND clearance for relapsed/refractory multiple myeloma
  • CARsgen won NMPA IND clearance for CT0596, an allogeneic BCMA-targeted CAR-T, in relapsed or refractory multiple myeloma.
  • The program is set to move into company-sponsored clinical testing in China, following encouraging early investigator-led trial signals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CARsgen Therapeutics Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260804-12269883), on August 04, 2026, and is solely responsible for the information contained therein.